Incyte公司的培美替尼去哪买的到？

For the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. As the first targeted drug for cholangiocarcinoma, pemetinib is expected to change the clinical treatment landscape for patients with cholangiocarcinoma. So, where can I buy Incyte’s pemetinib?

According to Medical Companion Travel, we have learned that the price of pemetinib is not fixed due to exchange rate fluctuations. For specific prices, you can consult the Medical Companion Travel Service. Patients in need can purchase the drug abroad or obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel), and have it shipped directly to their homes to ensure authenticity.

Pemetinib belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps stop or slow the spread of cancer cells.

American genetic engineering technology company, referred to as Genentech (Incyte), is the oldest biotechnology company in the United States and is currently the second largest biotechnology company in the world after Amgen in terms of scale and strength. In order to achieve the goal of becoming the world's largest oncology pharmaceutical company, Genentech suspended research on the long-acting recombinant human growth hormone Nutroppin Deptot and focused on the research and development of oncology drugs such as Avastin. Genentech is the earliest biotechnology pharmaceutical company established and the first to develop biotechnology drugs.

Pemetinib tablets are taken orally. Usually taken once daily with or without food during the first 14 days of a 21-day cycle. If the missed dose of pemetinib is less than 4 hours, take the missed dose as soon as possible and then take the next dose at the scheduled time. However, if a dose is missed by 4 hours or more, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose.

On April 17, 2020, the U.S. FDA announced accelerated approval of the FGFR2 inhibitor developed by Incyte to treat adult patients with previously treated advanced cholangiocarcinoma carrying FGFR2 gene fusions or other rearrangements. Pemetinib is the first targeted therapy approved to treat adults with advanced cholangiocarcinoma.

Recommended related hot articles: /newsDetail/96521.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.